ClinicalTrials.gg
CompletedNCT00901771Updated Jun 15, 2010

Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP

An interventional study of Provent in Sleep Apnea, Obstructive, sponsored by St. Luke's Hospital, Chesterfield, Missouri. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-06-15.

Sponsored by St. Luke's Hospital, Chesterfield, Missouri · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the proposed investigation is to evaluate the efficacy of the Provent device in a sample of OSA patients who have either refused or been non-adherent with PAP treatment. Both initial efficacy (evaluated after approximately one week with Provent) and efficacy after approximately 5 weeks in patients who demonstrate initial efficacy will be assessed. A secondary objective is to assess adherence with Provent treatment during the 5-week evaluation period.

02

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • Sleep
  • Sleep Apnea, Obstructive
  • OSA
  • OSAH
03

In context

Sleep Apnea, Obstructive

2,263 studies on the registry are indexed under Sleep Apnea, Obstructive; 465 are open to participants now.

This study's planned enrollment of 50 is close to the median of 53 across 1,490 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

St. Luke's Hospital, Chesterfield, Missouri is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current signs and symptoms consistent with a diagnosis of OSA in the opinion of the study physician
  • Rejection of PAP treatment or minimally adherent with PAP treatment
  • Use of the Provent device for a specified amount of time each night during three consecutive nights of the trial period
  • AHI > 15, or AHI > 10 with evidence of CMS-recognized symptoms or co- morbidities, on screening/baseline PSG
  • Investigator believes that subject can benefit from OSA treatment
  • Subject understands and is willing and able to comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Use of any device that interferes with nasal or oral breathing
  • Persistent blockage of one or both nostrils which prevents airflow in one or both nostrils
  • Any chronic sores or lesions on the inside or outside of the nose
  • Chronic use of nasal decongestants other than nasal steroids
  • History of allergic reaction to acrylic-based adhesives (such as those found in BAND-AIDS®)
  • Current acute upper respiratory (including nasal, sinus, or middle ear) inflammation or infection or perforation of the tympanic membrane (may be re-considered for participation after the acute episode resolves)
  • History of frequent and/or poorly treated severe nasal allergies or sinusitis which may interfere with the ability to use Provent
  • Severe respiratory disorders (including respiratory muscle weakness, bullous lung disease, bypassed upper airway, pneumothorax, pneumomediastinum, etc.).
  • Pathologically low blood pressure.
  • Narcolepsy, idiopathic hypersomnolence, chronic insomnia, restless legs syndrome, REM sleep behavior disorder or any other diagnosed or suspected sleep disorder other than OSA that could affect the likelihood of apneas/hypopneas during a PSG.
  • Periodic limb movement arousal index (PLMAI) > 10 on the screening/baseline PSG.
  • Current use of diurnal or nocturnal supplemental oxygen
  • Currently working night or rotating shifts
  • Consumption of > 10 caffeinated beverages per day (approximately 1000 mg per day)
  • History of severe cardiovascular disease, including New York Heart Association Class III or IV heart failure, coronary artery disease with angina or myocardial infarction in the past 6 months, stroke in the past 6 months
  • History of cardiac rhythm disturbance (defined as a 5-beat run of sustained ventricular tachycardia or bradycardia if \< 30 beats per min for a 10-second run or previously undiagnosed and untreated atrial fibrillation or Mobitz II or third-degree heart block)
  • Current psychiatric disorder with psychotic features.
  • Pregnant or trying to become pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Interventions

  • DeviceProvent

    This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.

06

What researchers measure

Primary outcomes

  1. Week 1 AHI as compared to Screening/Baseline AHI

    Time frame: 1 week

Secondary outcomes

  1. Week 5 AHI as compared to Screening/Baseline AHI

    Time frame: 5 weeks

  2. Minutes with SaO2 <90%: Week 5 vs. Screening/Baseline

    Time frame: 5 weeks

  3. Epworth Sleepiness Scale: Week 5 vs. Baseline

    Time frame: 5 weeks

07

Study locations

1 site
  • Sleep Medicine and Research Center at St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00901771
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Collaborators
Ventus Medical, Inc.
First posted
May 14, 2009
Start date
May 2009
Primary completion
Oct 2009
Completion
Dec 2009
Last update
Jun 15, 2010

Study contacts

James K Walsh, Ph.D.
principal investigator · Sleep Medicine and Research Center at St. Luke's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion